WO2007122981A1 - DÉRIVÉ DE COUMARINE SUSCEPTIBLE D'INHIBER LA MONOXYDE D'AZOTE SYNTHASE INDUCTIBLE (iNOS) - Google Patents
DÉRIVÉ DE COUMARINE SUSCEPTIBLE D'INHIBER LA MONOXYDE D'AZOTE SYNTHASE INDUCTIBLE (iNOS) Download PDFInfo
- Publication number
- WO2007122981A1 WO2007122981A1 PCT/JP2007/057378 JP2007057378W WO2007122981A1 WO 2007122981 A1 WO2007122981 A1 WO 2007122981A1 JP 2007057378 W JP2007057378 W JP 2007057378W WO 2007122981 A1 WO2007122981 A1 WO 2007122981A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inos
- substituent
- coumarin compound
- group
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a coumarin compound, more specifically, allergic airway inflammation, pneumonia, arthritis, vasculitis, spleen ⁇ 8 cell self-destruction, allograft acute rejection at the time of organ transplantation, etc.
- the present invention relates to a substance having iNOS inhibitory activity capable of suppressing a number of inflammatory diseases.
- Nitric oxide is an essential endogenous substance involved in various biological maintenance mechanisms, but also has a negative aspect of being a causative substance such as inflammation. It is thought that inducible monoxide-nitrogen synthase (iNOS) is involved in the production of NO, which works on this negative side, and finding compounds that inhibit iN OS can help create new anti-inflammatory drugs. It is thought to be connected.
- iNOS inducible monoxide-nitrogen synthase
- Non-Patent Document 1 Agric. Food Chem., 1999, 47 pp. 333-339
- Non-Patent Document 2 Bioorg. Med. Chem., 2000, 8 ⁇ , pp. 2701-2707
- Non-Patent Document 3 Chem. Pharm. Bull., 2004, 52 ⁇ , 1215-1218
- Non-patent Literature 4 Nat. Chem., 2004, 67 ⁇ , 432-436
- Non-Patent Document 5 Bioorg. Med. Chem., 2005, 13 ⁇ , pages 2723-2739 Disclosure of the Invention
- the present inventors conducted a screening test using iNOS inhibitory activity as an index for tropical plants, and found that a strong inhibitory activity was observed in the Citrus Clausena plant, and that the active body was a coumarin compound. As a result, the present invention has been completed.
- the coumarin compound that inhibits inducible monoacid-nitrogen synthase according to one embodiment of the present invention is represented by the following formula (1).
- X is a hydrogen atom or a substituent !, a hydrocarbon group or a substituent is an aryl group, and R and R are optionally substituted carbon atoms.
- Z is a hydrogen atom or a hydrocarbon group which may have a substituent.
- R, R, Y and Z are
- a coumarin compound that inhibits inducible nitric oxide synthase according to another embodiment of the present invention is represented by the following formula (2) or (3).
- a novel coumariny compound having stronger iNOS inhibitory activity can be provided, and an iNOS inhibitor using the same can be further provided.
- the coumarin compound according to the embodiment is a 5,7-dioxycoumarin compound represented by the following formula (1).
- X represents a hydrogen atom, a hydrocarbon group that may have a substituent, or an aryl group that may have a substituent.
- a hydrocarbon group the number of carbons is not limited, but is preferably in the range of 1 to 4.
- the substituent is not limited, but examples thereof include an aldehyde group, a ketone group, a hydroxyl group, an amino group, an alkoxy group, a carboxyl group, an alkoxycarbo group, a carbooxy group, and a halogen atom.
- R and R are hydrocarbon groups which may have a substituent
- the number of carbons is not limited but is preferably in the range of 1-4.
- examples of the hydrocarbon group are not limited, but examples thereof include methyl, ethyl, propyl, butyl, isobutyl, and t-butyl.
- the substituent is not limited, but examples thereof include an aldehyde group, a ketone group, a hydroxyl group, an amino group, an alkoxy group, a carboxyl group, an alkoxycarbo group, a carbooxy group, and a halogen atom. be able to.
- Y and Z are hydrocarbon groups which may have a hydrogen atom or a substituent, and Y and Z may be the same or different.
- the number of carbons in the hydrocarbon group is not limited, but a hydrocarbon group in the range of 2 to 5 may contain a double bond.
- the substituent is not limited, but for example, an aldehyde group, a ketone group, a hydroxyl group, an amino group, an alkoxy group, a carboxyl group, an alkoxycarbo group, a carbooxy group, or a halogen atom. I can give you.
- the method for obtaining the 5,7-dioxycoumariny compound represented by the above formula (1) is not limited and can be obtained by various methods.
- the present embodiment can provide a novel coumariny compound having iNOS inhibitory activity.
- the coumariny compound of the present embodiment can be used as an iNOS inhibitor.
- iNOS inhibitors are pharmaceutically acceptable ordinary carriers, binders, stabilizers, excipients, diluents, pH buffering agents, disintegrating agents, solubilizers, solubilizing aids. Ingredients for various preparations such as agents and isotonic agents can be added.
- an appropriate dose corresponding to the patient's sex, weight and symptoms can be administered orally or parenterally.
- compositions can be administered orally in commonly used dosage forms, such as powders, granules, capsules, syrups, suspensions, etc. These can be administered parenterally in the form of injections, and can also be administered intranasally in the form of sprays.
- the present inventors prepared a concentrated solution (lmgZml) by dissolving ethanol extract in dimethyl sulfoxide for a tropical plant, diluted to 5; ⁇ 71111, and used 1? ⁇ 03 inhibitory activity as an index.
- a screening test revealed strong inhibitory activity in Citrus Clausena plants, revealing that it is a coumariny compound with active activity.
- a plurality of coumarin compounds were prepared, each of which was dissolved in dimethyl sulfoxide and prepared as a concentrated solution (1 ⁇ M), and diluted as appropriate (1 to: LOOnM) to prepare test samples.
- Mouse macrophage RAW264.7 cells were seeded on a 24-well plate, cultured until semi-confluent, then changed to serum-free medium, and LPS (50 ng Zml) and the test sample were added. After 16 hours of incubation, the cells were homogenized and protein quantification followed by Western blotting to measure the expression levels of iNOS and TNF- ⁇ protein. (2J NO measurement
- xant hoxyletin derived from Clausena glauillauminii (see the compound represented by the following formula (A)).
- This xathoxyletin also inhibited other inflammation-related factors such as TNF- ⁇ expression and NO production in a concentration-dependent manner.
- xanthoxyletin represented by the formula (A) is a compound having a coumarin skeleton in its structure. Regarding coumarins, physiological functions such as antitumor activity, sensitization promotion, coronary vasodilatation, antibacterial action, and anti-inflammation Effects have been reported.
- the compounds (2) and (3) are those of TNF-a, which is a kind of inflammatory site force-in. It was also important to suppress protein expression relatively strongly.
- Table 2 shows the results of diluting a concentrated solution (1 ⁇ ) obtained by dissolving a coumarin compound in dimethyl sulfoxide to ⁇ .
- the coumariny compound according to the present invention has antiallergic airway inflammation activity, antipneumonitis activity, antiarthritis activity, antivasculitis activity, inhibition of splenocyte self-destruction, allograft acute rejection Expected to have reaction inhibition, it has industrial applicability as a drug that suppresses numerous inflammatory diseases (anti-inflammatory drug).
- FIG. 1 is a diagram showing the iNOS enzyme activity of the coumariny compound according to the example.
Abstract
La présente invention a pour objet un inhibiteur de monoxyde d'azote synthase inductible qui comprend un dérivé de coumarine de formule (1) et qui est particulièrement actif. (1) où X représente un atome d'hydrogène, un groupement hydrocarbure éventuellement substitué, ou un groupement aryle éventuellement substitué ; R1 et R2 représentent indépendamment un groupement hydrocarbure éventuellement substitué ; et Y et Z représentent indépendamment un atome d'hydrogène ou un groupement hydrocarbure éventuellement substitué, à la condition que R1, R2, Y et Z puissent être identiques ou différents les uns des autres.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006118234A JP2007290981A (ja) | 2006-04-21 | 2006-04-21 | 誘導型一酸化窒素合成酵素(iNOS)を阻害するクマリン化合物 |
JP2006-118234 | 2006-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007122981A1 true WO2007122981A1 (fr) | 2007-11-01 |
Family
ID=38624889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/057378 WO2007122981A1 (fr) | 2006-04-21 | 2007-04-02 | DÉRIVÉ DE COUMARINE SUSCEPTIBLE D'INHIBER LA MONOXYDE D'AZOTE SYNTHASE INDUCTIBLE (iNOS) |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2007290981A (fr) |
WO (1) | WO2007122981A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412084A (zh) * | 2015-11-20 | 2016-03-23 | 西安交通大学 | 长春七中sesibricin的抗炎应用及其提取方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6059510B2 (ja) * | 2012-11-05 | 2017-01-11 | 花王株式会社 | セラミド産生促進剤 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026143A1 (fr) * | 2003-09-05 | 2005-03-24 | Aventis Pharmaceuticals Inc. | Coumarines comme inhibiteurs de l'oxyde nitrique synthase inductible (inos) |
-
2006
- 2006-04-21 JP JP2006118234A patent/JP2007290981A/ja not_active Withdrawn
-
2007
- 2007-04-02 WO PCT/JP2007/057378 patent/WO2007122981A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026143A1 (fr) * | 2003-09-05 | 2005-03-24 | Aventis Pharmaceuticals Inc. | Coumarines comme inhibiteurs de l'oxyde nitrique synthase inductible (inos) |
Non-Patent Citations (5)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412084A (zh) * | 2015-11-20 | 2016-03-23 | 西安交通大学 | 长春七中sesibricin的抗炎应用及其提取方法 |
CN105412084B (zh) * | 2015-11-20 | 2019-04-12 | 西安交通大学 | 长春七中sesibricin的抗炎应用及其提取方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2007290981A (ja) | 2007-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Efferth et al. | Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin | |
Li et al. | Norathyriol suppresses skin cancers induced by solar ultraviolet radiation by targeting ERK kinases | |
Tao et al. | Anticancer activity and mechanism investigation of beauvericin isolated from secondary metabolites of the mangrove endophytic fungi | |
Nguyen et al. | Anti-inflammatory terpenylated coumarins from the leaves of Zanthoxylum schinifolium with α-glucosidase inhibitory activity | |
Chen et al. | Monascuspiloin induces apoptosis and autophagic cell death in human prostate cancer cells via the Akt and AMPK signaling pathways | |
Farooq et al. | Discovery of a secalonic acid derivative from Aspergillus aculeatus, an endophyte of Rosa damascena Mill., triggers apoptosis in MDA-MB-231 triple negative breast cancer cells | |
Li et al. | Anti-inflammatory effect of tetrahydrocoptisine from Corydalis impatiens is a function of possible inhibition of TNF-α, IL-6 and NO production in lipopolysaccharide-stimulated peritoneal macrophages through inhibiting NF-κB activation and MAPK pathway | |
CN101437510A (zh) | 用作乙酰胆碱酯酶抑制剂的药物组合物 | |
Wei et al. | Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines | |
Wu et al. | The anti-inflammatory activity of several flavonoids isolated from Murraya paniculata on murine macrophage cell line and gastric epithelial cell (GES-1) | |
Bömer et al. | Jasmonates induce Arabidopsis bioactivities selectively inhibiting the growth of breast cancer cells through CDC6 and mTOR | |
Moussa et al. | Caspicaiene: a new kaurene diterpene with anti-tubercular activity from an Aspergillus endophytic isolate in Gleditsia caspia desf | |
Cruz et al. | Screening and Antifungal Activity of a β-Carboline Derivative against Cryptococcus neoformans and C. gattii | |
Keshari et al. | 5H-benzo [h] thiazolo [2, 3-b] quinazolines ameliorate NDEA-induced hepatocellular carcinogenesis in rats through IL-6 downregulation along with oxidative and metabolic stress reduction | |
Ha et al. | Synthesis and biological evaluation of scutellaria flavone cyclaneaminol mannich base derivatives as novel CDK1 inhibitors | |
WO2007122981A1 (fr) | DÉRIVÉ DE COUMARINE SUSCEPTIBLE D'INHIBER LA MONOXYDE D'AZOTE SYNTHASE INDUCTIBLE (iNOS) | |
US8158165B2 (en) | Preventative treatment and remission of allergic diseases | |
Wei et al. | A combinatorial target screening strategy for deorphaning macromolecular targets of natural product | |
Wagal et al. | Studies in molecular modeling, in vitro CDK2 inhibition and antimetastatic activity of some synthetic flavones | |
Mahdavian et al. | Biological activities of fusarochromanone: a potent anti-cancer agent | |
Dey et al. | Plant extracts from central Asia showing antiinflammatory activities in gene expression assays | |
JP2012184195A (ja) | キシログラニンa及びb | |
Liu et al. | Systematic exploration of the potential material basis and molecular mechanism of the Mongolian medicine Nutmeg-5 in improving cardiac remodeling after myocardial infarction | |
CN111269230B (zh) | 蜡梅碱-2,3二酮及其制备方法和医药用途 | |
Bosco et al. | Pulchelloid A, a sesquiterpene lactone from the Canadian prairie plant Gaillardia aristata inhibits mitosis in human cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07740814 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07740814 Country of ref document: EP Kind code of ref document: A1 |